;PMID: 9635572
;source_file_759.mrg
;Release 0.9 of PennBioIE
;Funded by NSF ITR EIA-0205448

;0)section:[e:0..37] = [t:0..37]
;1)sentence:[e:42..156] = [t:42..156]
;2)section:[e:160..254] = [t:160..254]
;3)section:[e:258..358] = [t:258..358]
;4)sentence:[e:362..487] = [t:362..487]
;5)sentence:[e:488..687] = [t:488..687]
;6)sentence:[e:688..809] = [t:688..809]
;7)sentence:[e:810..946] = [t:810..946]
;8)sentence:[e:947..1207] = [t:947..1207]
;9)sentence:[e:1208..1479] = [t:1208..1479]
;10)section:[e:1483..1527] = [t:1483..1527]

;section 0 Span:0..37
;Cancer Res  1998 Jun 15;58(12):2524-7
(SEC
  (FRAG (DT:[0..6] Cancer) (NNP:[7..10] Res) (CD:[12..16] 1998)
        (NNP:[17..20] Jun) (CC:[21..27] 15;58-LRB-) (CD:[27..29] 12)
        (-RRB-:[29..30] -RRB-) (CD:[30..35] :2524) (::[35..36] -)
        (CD:[36..37] 7)))

;sentence 1 Span:42..156
;Activation of the beta-catenin gene in primary hepatocellular carcinomas by 
;somatic alterations involving exon 3.
;[60..72]:gene-rna:"beta-catenin"
;[81..114]:malignancy:"primary hepatocellular carcinomas"
;[119..138]:variation-event:"somatic alterations"
;[149..155]:variation-location:"exon 3"
(SENT
  (NP-HLN
    (NP (NN:[42..52] Activation))
    (PP (IN:[53..55] of)
      (NP (DT:[56..59] the) (NN:[60..72] beta-catenin) (NN:[73..77] gene)))
    (PP-LOC (IN:[78..80] in)
      (NP (JJ:[81..88] primary) (JJ:[89..103] hepatocellular)
          (NNS:[104..114] carcinomas)))
    (PP-MNR (IN:[115..117] by)
      (NP
        (NP (JJ:[119..126] somatic) (NNS:[127..138] alterations))
        (VP (VBG:[139..148] involving)
          (NP (NN:[149..153] exon) (CD:[154..155] 3)))))
    (.:[155..156] .)))

;section 2 Span:160..254
;Miyoshi Y, Iwao K, Nagasawa Y, Aihara T, Sasaki Y, Imaoka S, Murata M,
;Shimano  T, Nakamura Y.
(SEC
  (FRAG (NNP:[160..167] Miyoshi) (NNP:[168..169] Y) (,:[169..170] ,)
        (NNP:[171..175] Iwao) (NNP:[176..177] K) (,:[177..178] ,)
        (NNP:[179..187] Nagasawa) (NNP:[188..189] Y) (,:[189..190] ,)
        (NNP:[191..197] Aihara) (NNP:[198..199] T) (,:[199..200] ,)
        (NNP:[201..207] Sasaki) (NNP:[208..209] Y) (,:[209..210] ,)
        (NNP:[211..217] Imaoka) (NNP:[218..220] S,) (NNP:[221..227] Murata)
        (NNP:[228..230] M,) (NNP:[231..238] Shimano) (NNP:[240..241] T)
        (,:[241..242] ,) (NNP:[243..251] Nakamura) (NNP:[252..254] Y.)))

;section 3 Span:258..358
;Department of Medical Genetics, Biomedical Research Center, Osaka University 
;Medical School, Japan.
(SEC
  (FRAG (NNP:[258..268] Department) (IN:[269..271] of) (NNP:[272..279] Medical)
        (NNP:[280..288] Genetics) (,:[288..289] ,) (NNP:[290..300] Biomedical)
        (NNP:[301..309] Research) (NNP:[310..316] Center) (IN:[316..317] ,)
        (NNP:[318..323] Osaka) (NNP:[324..334] University)
        (NNP:[336..343] Medical) (NNP:[344..350] School) (,:[350..351] ,)
        (NNP:[352..357] Japan) (.:[357..358] .)))

;sentence 4 Span:362..487
;We screened 75 primary hepatocellular carcinomas for somatic mutations in the
; entire coding region of the beta-catenin gene.
;[377..410]:malignancy:"primary hepatocellular carcinomas"
;[415..432]:variation-event:"somatic mutations"
;[469..481]:gene-rna:"beta-catenin"
(SENT
  (S
    (NP-SBJ (PRP:[362..364] We))
    (VP (VBD:[365..373] screened)
      (NP (CD:[374..376] 75)
         (JJ:[377..384] primary) (JJ:[385..399] hepatocellular)
         (NNS:[400..410] carcinomas))
      (PP-PRP (IN:[411..414] for)
        (NP
          (NP (JJ:[415..422] somatic) (NNS:[423..432] mutations))
          (PP-LOC (IN:[433..435] in)
            (NP
              (NP (DT:[436..439] the) (JJ:[441..447] entire)
                  (NN:[448..454] coding) (NN:[455..461] region))
              (PP (IN:[462..464] of)
                (NP (DT:[465..468] the) (NN:[469..481] beta-catenin)
                    (NN:[482..486] gene))))))))
    (.:[486..487] .)))

;sentence 5 Span:488..687
;We detected somatic mutations in  14 tumors; 12 were considered to cause
;amino acid substitutions and 2 were  interstitial deletions of 51 or 195
;nucleotides of genomic DNA, corresponding to  exon 3.
;[500..517]:variation-event:"somatic mutations"
;[525..531]:malignancy:"tumors"
;[561..585]:variation-type:"amino acid substitutions"
;[598..620]:variation-type:"interstitial deletions"
;[680..686]:variation-location:"exon 3"
(SENT
  (S
    (S
      (NP-SBJ (PRP:[488..490] We))
      (VP (VBD:[491..499] detected)
        (NP (JJ:[500..507] somatic) (NNS:[508..517] mutations))
        (PP-LOC (IN:[518..520] in)
          (NP (CD:[522..524] 14) (NNS:[525..531] tumors)))))
    (::[531..532] ;)
    (S
      (S
        (NP-SBJ-1 (CD:[533..535] 12))
        (VP (VBD:[536..540] were)
          (VP (VBN:[541..551] considered)
            (S
              (NP-SBJ-1 (-NONE-:[551..551] *))
              (VP (TO:[552..554] to)
                (VP (VB:[555..560] cause)
                  (NP
                    (NML (JJ:[561..566] amino) (NN:[567..571] acid))
                    (NNS:[572..585] substitutions))))))))
      (CC:[586..589] and)
      (S
        (NP-SBJ (CD:[590..591] 2))
        (VP (VBD:[592..596] were)
          (NP-PRD
            (NP (JJ:[598..610] interstitial) (NNS:[611..620] deletions))
            (PP (IN:[621..623] of)
              (NP
                (NP
                  (QP (CD:[624..626] 51) (CC:[627..629] or) (CD:[630..633] 195))
                  (NNS:[634..645] nucleotides))
                (PP (IN:[646..648] of)
                  (NP (JJ:[649..656] genomic) (NN:[657..660] DNA))))))
          (,:[660..661] ,)
          (S-ADV
            (NP-SBJ (-NONE-:[661..661] *))
            (VP (VBG:[662..675] corresponding)
              (PP-CLR (TO:[676..678] to)
                (NP (NN:[680..684] exon) (CD:[685..686] 3))))))))
    (.:[686..687] .)))

;sentence 6 Span:688..809
;Among the 12 point mutations, 6 occurred at potential serine/threonine 
;phosphorylation residues of codons 33, 41, or 45.
;[701..716]:variation-type:"point mutations"
;[788..797]:variation-location:"codons 33"
;[788..794]...[806..808]:variation-location:"codons"..."45"
;[788..794]...[799..801]:variation-location:"codons"..."41"
(SENT
  (S
    (PP (IN:[688..693] Among)
      (NP (DT:[694..697] the) (CD:[698..700] 12)
         (NN:[701..706] point) (NNS:[707..716] mutations)))
    (,:[716..717] ,)
    (NP-SBJ (CD:[718..719] 6))
    (VP (VBD:[720..728] occurred)
      (PP-LOC (IN:[729..731] at)
        (NP
          (NP (JJ:[732..741] potential)
            (NP
              (NML (NN:[742..748] serine) (SYM:[748..749] /)
                   (NN:[749..758] threonine))
              (NN:[760..775] phosphorylation))
            (NNS:[776..784] residues))
          (PP (IN:[785..787] of)
            (NP
              (NP
                (NML-1 (NNS:[788..794] codons))
                (CD:[795..797] 33))
              (,:[797..798] ,)
              (NP
                (NML-1 (-NONE-:[798..798] *P*))
                (CD:[799..801] 41))
              (,:[801..802] ,) (CC:[803..805] or)
              (NP
                (NML-1 (-NONE-:[805..805] *P*))
                (CD:[806..808] 45)))))))
    (.:[808..809] .)))

;sentence 7 Span:810..946
;The remaining six tumors  contained a mutation at codon 32 (aspartic acid) or
;34 (glycine), flanking to  the serine residue at codon 33.
;[828..834]:malignancy:"tumors"
;[848..856]:variation-event:"mutation"
;[860..868]:variation-location:"codon 32"
;[860..865]...[888..890]:variation-location:"codon"..."34"
;[870..883]:variation-state-generic:"aspartic acid"
;[892..899]:variation-state-generic:"glycine"
;[937..945]:variation-location:"codon 33"
(SENT
  (S
    (NP-SBJ (DT:[810..813] The) (VBG:[814..823] remaining) (CD:[824..827] six)
            (NNS:[828..834] tumors))
    (VP (VBD:[836..845] contained)
      (NP
        (NP (DT:[846..847] a) (NN:[848..856] mutation))
        (PP-LOC (IN:[857..859] at)
          (NP
            (NP
              
              (NML-1 (NN:[860..865] codon))
              (CD:[866..868] 32)
              (PRN (-LRB-:[869..870] -LRB-)
                (NP (JJ:[870..878] aspartic) (NN:[879..883] acid))
                (-RRB-:[883..884] -RRB-)))
            (CC:[885..887] or)
            (NP
              (NML-1 (-NONE-:[887..887] *P*))
              (CD:[888..890] 34)
              (PRN (-LRB-:[891..892] -LRB-)
                (NP (NN:[892..899] glycine))
                (-RRB-:[899..900] -RRB-))))))
      (,:[900..901] ,)
      (S-ADV
        (NP-SBJ (-NONE-:[901..901] *))
        (VP (VBG:[902..910] flanking)
          (PP (TO:[911..913] to)
            (NP (DT:[915..918] the) (NN:[919..925] serine)
                (NN:[926..933] residue)))
          (PP-LOC (IN:[934..936] at)
            (NP (NN:[937..942] codon) (CD:[943..945] 33))))))
    (.:[945..946] .)))

;sentence 8 Span:947..1207
;By Western blot analysis, we confirmed  accumulation of beta-catenin in five
;tumors for which frozen tissues were  available; the five included tumors in
;which amino acid alterations had occurred  at codons 32, 34, or 45, and one
;with a 17-amino acid deletion.
;[1003..1015]:gene-protein:"beta-catenin"
;[1024..1030]:malignancy:"tumors"
;[1091..1097]:malignancy:"tumors"
;[1107..1129]:variation-event:"amino acid alterations"
;[1147..1156]:variation-location:"codons 32"
;[1147..1153]...[1165..1167]:variation-location:"codons"..."45"
;[1147..1153]...[1158..1160]:variation-location:"codons"..."34"
;[1187..1206]:variation-type:"amino acid deletion"
(SENT
  (S
    (S
      (PP (IN:[947..949] By)
        (NP
          (NML (JJ:[950..957] Western) (NN:[958..962] blot))
          (NN:[963..971] analysis)))
      (,:[971..972] ,)
      (NP-SBJ (PRP:[973..975] we))
      (VP (VBD:[976..985] confirmed)
        (NP
          (NP (NN:[987..999] accumulation))
          (PP (IN:[1000..1002] of)
            (NP (NN:[1003..1015] beta-catenin))))
        (PP-LOC (IN:[1016..1018] in)
          (NP
            (NP (CD:[1019..1023] five) (NNS:[1024..1030] tumors))
            (SBAR
              (WHPP-1 (IN:[1031..1034] for)
                (WHNP (WDT:[1035..1040] which)))
              (S
                (NP-SBJ (JJ:[1041..1047] frozen) (NNS:[1048..1055] tissues))
                (VP (VBD:[1056..1060] were)
                  (ADJP-PRD (JJ:[1062..1071] available))
                  (PP-1 (-NONE-:[1071..1071] *T*)))))))))
    (::[1071..1072] ;)
    (S
      (NP-SBJ (DT:[1073..1076] the) (CD:[1077..1081] five))
      (VP (VBD:[1082..1090] included)
        (NP
          (NP (NNS:[1091..1097] tumors))
          (SBAR
            (WHPP-2 (IN:[1098..1100] in)
              (WHNP (WDT:[1101..1106] which)))
            (S
              (NP-SBJ
                (NML (JJ:[1107..1112] amino) (NN:[1113..1117] acid))
                (NNS:[1118..1129] alterations))
              (VP (VBD:[1130..1133] had)
                (VP (VBN:[1134..1142] occurred)
                  (PP-LOC (IN:[1144..1146] at)
                    (NP
                      (NP
                        (NML-3 (NNS:[1147..1153] codons))
                        (CD:[1154..1156] 32))
                      (,:[1156..1157] ,)
                      (NP
                        (NML-3 (-NONE-:[1157..1157] *P*))
                        (CD:[1158..1160] 34))
                      (,:[1160..1161] ,) (CC:[1162..1164] or)
                      (NP
                        (NML-3 (-NONE-:[1164..1164] *P*))
                        (CD:[1165..1167] 45))
                      (,:[1167..1168] ,) (CC:[1169..1172] and)
                      (NP
                        (NP (CD:[1173..1176] one))
                        (PP (IN:[1177..1181] with)
                          (NP (DT:[1182..1183] a)
                            (NML (CD:[1184..1186] 17) (HYPH:[1186..1187] -)
                                 (JJ:[1187..1192] amino) (NN:[1193..1197] acid))
                            (NN:[1198..1206] deletion))))))
                  (PP-2 (-NONE-:[1206..1206] *T*)))))))))
    (.:[1206..1207] .)))

;sentence 9 Span:1208..1479
;Our results  suggested that accumulation of beta-catenin due to amino acid
;substitutions at  potential serine/threonine phosphorylation residues or at
;their neighboring  codons or interstitial deletions involving exon 3 could
;contribute to  hepatocellular carcinogenesis.
;[1252..1264]:gene-protein:"beta-catenin"
;[1272..1296]:variation-type:"amino acid substitutions"
;[1388..1410]:variation-type:"interstitial deletions"
;[1421..1427]:variation-location:"exon 3"
(SENT
  (S
    (NP-SBJ (PRP$:[1208..1211] Our) (NNS:[1212..1219] results))
    (VP (VBD:[1221..1230] suggested)
      (SBAR (IN:[1231..1235] that)
        (S
          (NP-SBJ
            (NP (NN:[1236..1248] accumulation))
            (PP (IN:[1249..1251] of)
              (NP (NN:[1252..1264] beta-catenin)))
            (PP (IN:[1265..1268] due)
              (PP (TO:[1269..1271] to)
                (NP
                  (NP
                    (NML (JJ:[1272..1277] amino) (NN:[1278..1282] acid))
                    (NNS:[1283..1296] substitutions))
                  (PP-LOC
                    (PP (IN:[1297..1299] at)
                      (NP (JJ:[1301..1310] potential)
                        (NML
                          (NML (NN:[1311..1317] serine) (SYM:[1317..1318] /)
                               (NN:[1318..1327] threonine))
                          (NN:[1328..1343] phosphorylation))
                        (NNS:[1344..1352] residues)))
                    (CC:[1353..1355] or)
                    (PP (IN:[1356..1358] at)
                      (NP
                        (NP (PRP$:[1359..1364] their)
                            (VBG:[1365..1376] neighboring)
                            (NNS:[1378..1384] codons))
                        (CC:[1385..1387] or)
                        (NP
                          (NP (JJ:[1388..1400] interstitial)
                              (NNS:[1401..1410] deletions))
                          (VP (VBG:[1411..1420] involving)
                            (NP (NN:[1421..1425] exon) (CD:[1426..1427] 3)))))))))))
          (VP (MD:[1428..1433] could)
            (VP (VB:[1434..1444] contribute)
              (PP-CLR (TO:[1445..1447] to)
                (NP (JJ:[1449..1463] hepatocellular)
                    (NN:[1464..1478] carcinogenesis))))))))
    (.:[1478..1479] .)))

;section 10 Span:1483..1527
;PMID: 9635572 [PubMed - indexed for MEDLINE]
(SEC
  (FRAG (NNP:[1483..1487] PMID) (::[1487..1488] :) (CD:[1489..1496] 9635572)
        (NN:[1497..1498] -LSB-) (NNP:[1498..1504] PubMed) (::[1505..1506] -)
        (NN:[1507..1514] indexed) (IN:[1515..1518] for)
        (NNP:[1519..1527] MEDLINE-RSB-)))
